Over the last 12 months, Ultragenyx Pharmaceutical insiders reported no purchases and 24 sales totaling $3.7M across SEC Form 4 filings. 50% of those filings were made under pre-arranged 10b5-1 trading plans.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Decision | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | Non-discretionarytax on vesting | 7,066 | $15.27 | $108K | -7.3% | — |
| Sep 15, 2026 | Huizenga Theodore AlanSVP, Chief Accounting Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 1,283 | $13.57 | $17K | -1.9% | — |
| Sep 3, 2026 | Huizenga Theodore AlanSVP, Chief Accounting Officer · O | ▼ Sale | Non-discretionarytax on vesting | 161 | $13.99 | $2K | -0.2% | — |
| Aug 3, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 1,900 | $24.92 | $47K | -2% | — |
| Aug 3, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 4,696 | $24.92 | $117K | -4.6% | — |
| Jul 1, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 4,698 | $33.13 | $156K | -4.4% | — |
| Jun 15, 2026 | Sanders Corazon (Corsee) D.D | ▼ Sale | Discretionaryopen market | 2,000 | $25.05 | $50K | -8.7% | — |
| Jun 15, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 1,899 | $24.62 | $47K | -2% | — |
| Jun 1, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 4,653 | $23.77 | $111K | -4.2% | — |
| May 5, 2026 | Crombez EricEVP and Chief Medical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 344 | $24.96 | $9K | -0.3% | — |
| May 1, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 4,683 | $24.9 | $117K | -4.1% | — |
| Apr 1, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 4,683 | $20.97 | $98K | -5.5% | — |
| Mar 10, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer · O | ▼ Sale | Discretionaryopen market | 9,526 | $21.87 | $208K | -12.5% | 2 tranches |
| Mar 3, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 10,044 | $22.65 | $228K | -10.6% | 3 tranches |
| Mar 2, 2026 | Pinion John RichardSee Remarks · O | ▼ Sale | Non-discretionarytax on vesting | 10,029 | $22.8 | $229K | -8.4% | — |
| Mar 2, 2026 | Harris ErikEVP & Chief Commercial Officer · O | ▼ Sale | Non-discretionarytax on vesting | 10,539 | $22.8 | $240K | -10.5% | — |
| Mar 2, 2026 | KAKKIS EMIL DPresident & CEO · O·D | ▼ Sale | Non-discretionarytax on vesting | 54,404 | $22.8 | $1.2M | -7.6% | — |
| Mar 2, 2026 | Parschauer Karah HerdmanEVP and Chief Legal Officer · O | ▼ Sale | Non-discretionarytax on vesting | 8,135 | $22.8 | $185K | -9.6% | — |
| Mar 2, 2026 | Huizenga Theodore AlanSVP, Chief Accounting Officer · O | ▼ Sale | Non-discretionarytax on vesting | 1,632 | $22.8 | $37K | -3.2% | — |
| Mar 2, 2026 | Crombez EricEVP and Chief Medical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 7,029 | $22.8 | $160K | -8.4% | — |
| Feb 2, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 3,061 | $23.56 | $72K | -3.3% | — |
| Jan 2, 2026 | Horn HowardChief Financial Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 3,150 | $22.84 | $72K | -3.3% | — |
| Dec 29, 2025 | Huizenga Theodore AlanSVP, Chief Accounting Officer · O | ▼ Sale | Non-discretionarytax on vesting | 85 | $34.38 | $3K | -0.2% | — |
| Dec 10, 2025 | Horn HowardChief Financial Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 3,081 | $36.38 | $112K | -3.1% | — |
| Oct 13, 2025 | Horn HowardChief Financial Officer · O | ▼ Sale | Non-discretionarytax on vesting | 7,942 | $31.51 | $250K | -7.5% | — |
| Sep 18, 2025 | Huizenga Theodore AlanSVP, Chief Accounting Officer · O | ▼ Sale | Non-discretionarytax on vesting | 64 | $29.17 | $2K | -0.1% | — |
| Sep 12, 2025 | Parschauer Karah HerdmanEVP and Chief Legal Officer · O | ▼ Sale | Discretionaryopen market | 2,450 | $31.17 | $76K | -3.2% | — |
| Sep 5, 2025 | Huizenga Theodore AlanSVP, Chief Accounting Officer · O | ▼ Sale | Non-discretionarytax on vesting | 84 | $31.39 | $3K | -0.2% | — |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Ultragenyx Pharmaceutical filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RARE feed.